However, from a tumor-intrinsic perspective, whether shortening the CDK4/6i dosing schedule would significantly compromise the tumor-intrinsic efficacy of BRAFi/MEKi+CDK4/6i, in regards to maintaining RB activation, requires further investigation. The gene discussed is RB1; the disease is neoplasm.